Cancer Research UK
Therapeutic Catalyst - Early Therapy Award
Further cut-offs 21 May 2027, 17 September 2027
Last seen in a scan/import: .
Catalog updated: .
These timestamps are not source verification. Confirm the current deadline and your eligibility on the funder’s call page before applying.
The Therapeutic Catalyst - Early Therapy Award from Cancer Research UK funds up to £350K over 18-24 months for hit identification, druggability assessment, and early development of antibody or small molecule cancer therapeutics. It is open to academic researchers worldwide who run their own lab, and projects are delivered collaboratively with Cancer Research Horizons' drug discovery team. The scheme runs three times a year with a two-stage, invitation-only application process.
Details
| Funder | Cancer Research UK |
| Budget | Up to £350K |
| Deadline | 5 February 2027 |
| Duration | 18-24 months |
| Consortium | No - individual applicant, collaborative project run with Cancer Research Horizons' drug discovery team |
| Application | 2-stage: expression of interest → full proposal, by invitation only |
| Frequency | Three times per year |
Eligibility & scope
Funds hit identification, druggability assessment, and further development of early therapeutic projects for adult cancers using antibody or small molecule approaches. Open to academic researchers worldwide with their own lab; run collaboratively with Cancer Research Horizons.
Who Should Apply
- •Academic researchers worldwide who run their own independent lab
- •Projects focused on hit identification or druggability assessment for adult cancers
- •Teams working with antibody or small molecule therapeutic approaches
- •Researchers willing to collaborate closely with Cancer Research Horizons' drug discovery team
Key Dates
- •Next deadline 5 February 2027, with further cut-offs 21 May 2027 and 17 September 2027
- •Two-stage process: expression of interest, then full proposal by invitation only
- •18-24 month project duration
Tips for Applicants
- ✓Expression of interest is the real filter - only invited applicants proceed to full proposal, so make the druggability rationale and hit-finding strategy clear upfront.
- ✓Frame the project as a genuine collaboration with Cancer Research Horizons' drug discovery team rather than a standalone academic study.
- ✓With three calls per year, a rejected expression of interest can be revised and resubmitted to the next cut-off rather than waiting a full year.
Frequently Asked Questions
How much does the CRUK Therapeutic Catalyst Early Therapy Award pay?
Up to £350,000 for a project lasting 18-24 months.
Who can apply for the Therapeutic Catalyst Early Therapy Award?
Academic researchers anywhere in the world who have their own lab and are working on antibody or small molecule approaches to adult cancers.
Does this award require a consortium?
No, it is for individual applicants, though the project is run collaboratively with Cancer Research Horizons' drug discovery team.
How often can I apply to this CRUK scheme?
The call runs three times a year, with cut-offs on 5 February 2027, 21 May 2027, and 17 September 2027.
What is the application process for this award?
It is a two-stage process: an expression of interest followed by a full proposal, with the full proposal stage by invitation only.
Summary generated by AI based on published grant information. Always verify details on the funder's website.
Similar grants
Therapeutic Catalyst - Target Award
Cancer Research UKDeadline: 5 Feb 2027Up to £250KChildhood Cancer Therapeutic Catalyst
Cancer Research UKUp to £250kDrug Development Project
Cancer Research UKEarly Detection and Diagnosis Project Award
Cancer Research UKDeadline: 3 Dec 2026Up to £500kEarly Detection and Diagnosis Primer Award
Cancer Research UKDeadline: 11 Mar 2027Up to £100k
Browse Related
Could Therapeutic Catalyst - Early Therapy Award be right for you?
See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →